×

Santen Reports Fiscal 2015 Consolidated Performance

OSAKA, Japan, May 11, 2016 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. (Osaka, JAPAN, Tokyo Stock Exchange Code 4536) (Santen) today announced consolidated performance for fiscal 2015 ended March 31, 2016 as well as guidance for fiscal 2016.

Commenting on the announcement, Akira Kurokawa, President and CEO of Santen, said:

"In fiscal 2015, Santen’s revenue and operating profit both grew by double-digit percentages to reach record high levels. In Japan, revenue maintained positive momentum with growth of 14% boosted by the sales of new products including EYLEA and Alesion. Overseas revenue grew 44% with contributions from products acquired from Merck & Co., Inc. in 2014 as well as Ikervis which was approved and launched in Europe in 2015.

“Our achievements in fiscal 2015 and outlook for fiscal 2016 represent good progress in our Medium-Term Management Plan which focuses on the areas of product development, business expansion, organization and talent. This plan is based on our vision to develop Santen into a specialized pharmaceutical company with a global presence by 2020.”

Summary of results and forecasts

IFRS basisFY15 actual
(million yen)
change
(YoY %)
FY16 forecast
(million yen)
change
(YoY %)
Revenue195,291 +20.7%204,000 +4.5%
Operating profit 80,180 +126.7%38,700 -51.7%
Net profit for the period 53,373 +122.1%26,900 -49.6%
Earnings per share (basic)¥ 128.99 ¥ 64.95


Core basis*

FY15 actual
(million yen)
change
(YoY %)
FY16 forecast
(million yen)
change
(YoY %)
Revenue195,291 +20.7%204,000 +4.5%
Core operating profit43,067 +10.2%46,000 +6.8%
Core net profit for the period29,163 +12.4%31,800 +9.0%

* Core basis results are non-IFRS measures that remove non-core items including amortization associated with products, other revenue and expenses, and financial revenue and expenses in order to provide greater transparency on underlying business performance.

On August 3, 2015, Santen completed the simplified company split relating to the transfer of its anti-rheumatic pharmaceutical business to AYUMI Pharmaceutical Corporation. The one-time gain related to the transaction resulted in a 45 billion yen positive impact as other income in Santen's FY15 operating profit (IFRS basis).

Additional investor relations and other materials about Santen are available on the company’s website (http://www.santen.com/en/ir/).

About Santen
As a specialty company dedicated to the ophthalmic field, Santen carries out research, development, sales, and marketing of pharmaceuticals. Santen is the market leader in Japan for prescription ophthalmic pharmaceuticals and sells products in over 50 countries. As a leading company in the field of ophthalmology, Santen aims to contribute to society by supplying valuable products and services to satisfy unmet medical needs. For more details, please see Santen’s website (www.santen.com).

Santen Forward-looking Statements
Information provided in this news release contains so-called “Forward-looking Statements”. The realizations of these forecasts are subject to risk and uncertainty from various sources. Therefore, please note that the actual results may differ significantly from the forecasts. Business performance and financial condition are subject to the effects of changes in regulations made by the governments of Japan and other nations concerning medical insurance, drug pricing and other systems, and to fluctuations in market variables such as interest rates and foreign exchange rates.

Contact
Christopher Hohman
General Manager
Corporate Communications Group
Santen Pharmaceutical Co., Ltd.
E-mail: ir@santen.co.jp
Tel: +81-6-4802-9360

Source: Santen Pharmaceutical Co., Ltd.